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Main point 
Older children and adolescents with HIV and receiving ART in Sub-Saharan Africa have a high 
incidence of echocardiographic abnormalities which are likely primary HIV-related heart muscle 
disease. The abnormalities have a potential for progression over time. 
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Abstract 
Background 
A high prevalence of cardiac abnormalities has been reported in children with HIV taking ART 
in sub-Saharan Africa. We investigated the incidence and progression of cardiac abnormalities 
among children taking ART in Zimbabwe. 
Methods  
A prospective cohort study was conducted at a paediatric HIV clinic from 2014 to 2017. 
Children with HIV aged between 6 and 16 years and taking ART ≥6 months were enrolled. 
Transthoracic echocardiography was performed at baseline and 18 months.  
Results 
Of 197 participants recruited at baseline, 175 [(89%), 48% female, median age 12 (IQR, 10-
14) years] were followed up. The incidence of left and right heart abnormalities was 3.52 and 
5.64 per 100 pys, respectively. Stunting was associated with the development of any cardiac 
abnormality [adjusted OR 2.59 (95% CI, 1.03-6.49); p=0.043]. Right ventricular (RV) 
dilatation persisted at follow up in 92% and left ventricular (LV) diastolic dysfunction in 88%. 
Cardiac abnormalities present at baseline reverted to normal over the follow up period in 
11(6%). There was an overall increase in mean z-scores for LV, left atrium (LA), RV, 
interventricular septum and LV posterior wall diameters at 18 months (p<0.001). 
Conclusions 
Despite ART, children with HIV have a high incidence of cardiac abnormalities, with only a 
minority being transient. Mean z-scores for LV, LA, RV, interventricular septum and LV 
posterior wall diameters increased over a relatively short follow up period, suggesting the 
potential for progression of cardiac abnormalities. Longer follow up is required to understand 
the clinical implications of these abnormalities. 
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Introduction 
 
The global scale-up of antiretroviral therapy (ART) programmes has been followed by a 
dramatic decline in mortality among individuals living with HIV infection [1]. While ART 
facilitates immune reconstitution and reduces the risk of infections, there is increased 
recognition that longstanding HIV infection is associated with an increased risk of chronic co-
morbidities. This may be a result of the HIV infection itself, its treatment or sequelae of 
infections [2]. One of the most well-recognised co-morbidities is cardiac disease, with several 
studies showing an increased risk of developing cardiac disease in adults despite ART [3, 4]. 
An important limitation of studies in adults is confounding by well-established risk factors for 
cardiac disease such as age, smoking and hypertension [4]. 
 
In the pre-ART era, infants and younger children with HIV were also reported to be at increased 
risk of developing cardiac disease, with a five-year cumulative incidence of cardiac dysfunction 
of 18-39% [5]. The most commonly reported abnormalities were left ventricular (LV) systolic 
dysfunction and LV dilatation; these were often progressive and were a predictor of all-cause 
mortality [6, 7]. Most of these studies were conducted in high-income settings, mainly in 
younger children and with some cohorts including children taking monotherapy for treatment 
of HIV infection [5, 7]. In high-income countries most children start ART in infancy, which 
not only decreases mortality but may prevent organ damage; [8] in these settings, the incidence 
of cardiac disease in children on ART has declined [9]. These findings cannot be generalised 
to children growing up with HIV in Sub-Saharan Africa (SSA), where 90% of the world’s 
children with HIV live, most of whom have had delayed diagnosis of HIV and/or started ART 
in older childhood [10, 11].  
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Nevertheless, increasing numbers of children in SSA, who would have died in early childhood, 
are now reaching adolescence and adulthood due to ART [12]. We and others have reported a 
high prevalence of cardiac abnormalities among African children despite treatment with ART 
and absence of the traditional risk factors for cardiac disease[13, 14]. However, little is known 
about the incidence and clinical course of cardiac abnormalities in African children in the ART 
era. We investigated the incidence and progression of cardiac abnormalities in children taking 
ART in Harare, Zimbabwe. 
 
Methods 
A prospective cohort study was conducted from August 2014 to December 2017 at the 
paediatric HIV clinic at Harare Central Hospital, Zimbabwe, a public-sector HIV clinic that 
provides care to over 4000 children. ART is provided free of charge according to national 
guidelines. This study was part of a larger study aiming to investigate cardiorespiratory disease 
in children with HIV infection taking ART [INHALE (Investigation of Heart and Lung 
Diseases in HIV among older children)]. Baseline cardiac findings in this cohort of HIV 
infected children have recently been reported [13]. Findings from this cohort pertaining to 
chronic lung disease have also been published [15, 16].  
 
Participants 
Children with HIV aged 6 to16 years attending the outpatient HIV clinic, taking ART for at 
least six months and clinically stable (defined as not requiring hospital admission and not too 
ill to participate) were consecutively enrolled on week days, limited to the first five eligible 
participants per day for logistical ease, as previously described [13]. Participants were followed 
up at 18 months.  
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Study procedures 
An interviewer-administered questionnaire was used to collect socio-demographic data and 
clinical history. Assessment of pubertal stage was based on Tanner staging [17]. Clinical 
assessment included measurement of height, weight, heart and respiratory rates and blood 
pressure, pulse oximetry, spirometry, HIV viral load and CD4 count tests and a transthoracic 
echocardiogram (full methods in supplementary data 1). The methods and definitions of this 
study have also been previously described [13].   
 
Data management and statistical analysis 
Data were extracted from paper forms using optical character recognition software (Cardiff 
TELEFORM Intelligent Character, Version 10.7) and analysed using STATA version 12 
software (StataCorp, Texas, USA). Continuous data were presented as mean ± standard 
deviation (SD) if they were normally distributed or median (interquartile range, IQR) if not 
normally distributed. A paired t-test, Mann-Whitney and McNemar tests were used to compare 
clinical characteristics of participants and mean values of cardiac measures and z-scores at 
baseline and follow up. There was temporal blinding during analysis of echocardiograms at 
follow-up. The mean change in z-scores for each cardiac measure was calculated as mean z-
score (18 months) minus mean z-score (baseline) and adjusted for baseline z-scores using linear 
regression. The incidence rate and risk for right and left heart abnormalities respectively were 
calculated in those without abnormalities at baseline, and risk is reported as a proportion. 
Logistic regression was used to assess for risk factors for incident cardiac abnormalities at 
follow up. These included baseline HIV-related and clinical factors. As previously described, 
HIV-related factors were categorised as CD4 cell count (>200 cells/µl and ≤200 cells/µl), HIV 
viral load (≤400 copies/µl and >400 copies/µl), age at ART initiation (0–5, 6–10 and 11–16 
years), duration on ART (≤2 years and >2 years) [13].  Age (categorised as 6–10 years and 11–
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16 years) and sex were included as a priori variables. Antiretroviral drugs including nevirapine 
and zidovudine were also assessed. HIV-related variables with a p-value ≤ 0.1 were retained 
for inclusion in the multivariate model and clinical factors were added into the model one at a 
time and those which were significant at p≤ 0.1 was retained for inclusion in the final model. 
We explored the association between baseline factors as linear variables and mean change in 
z-scores for cardiac measures, adjusted for baseline z-scores using linear regression. A p-value 
≤0.05 was considered statistically significant. 
Ethical approval was obtained from the Medical Research Council of Zimbabwe, the London 
School of Hygiene and Tropical Medicine Ethics Committee, the Biomedical Research and 
Training Institute Institutional Review Board and the Harare Central Hospital Ethics 
Committee.  Written informed consent from guardians and assent from participants was 
obtained prior to enrolment. 
Results 
Clinical characteristics 
A total of 197 participants were recruited of whom 175 (89%) were followed up at 18 months, 
giving 283.9 person-years (pys) of follow up (Figure 1). The median age of participants at 18 
months follow up was 12 (IQR, 10-14) years and 84 (48 %) were female. Forty percent of 
participants were virally suppressed (<400 copies/ml) at 18 months compared to 78% at 
baseline (p<0.001; Table 1). Supplementary Figure 1 shows the flow diagram of viral 
suppression over time. Four participants died, all of whom had echocardiographic 
abnormalities at baseline. The causes of death were pulmonary tuberculosis; meningitis; 
cardiac failure due to dilated cardiomyopathy; and unknown. The 22 participants lost to follow 
up either relocated or were unreachable due to change of contact details. There were no 
significant differences in age, CD4 count, viral load, duration on ART, clinical characteristics, 
height-for-age and weight-for-age z-scores and cardiac dimensions z-scores at baseline 
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between participants who were followed up and those lost to follow up. Data on pubertal 
staging were available at follow up on all participants. Thirty (35%) participants had reached 
menarche. Of the female participants, 34 (40%) and 40 (48%) were in Tanner stage 1 of breast 
and pubic hair development, respectively, compared to 3 (3%) testicular volume and 66 (73%) 
pubic hair development of the male participants (data not shown).  
Echocardiographic findings 
Baseline echocardiographic findings have been previously reported.[13] Briefly, at baseline, 
40 participants (23%) had LV diastolic dysfunction; 18 (10%) had LVH; 14 (8%) had LA 
dilatation; RV systolic dysfunction in  2 (1%) and 12 (7%) had RV dilatation. At 18 months, 
23 (13%) participants had RV dilatation and 6 (3%) had RV systolic dysfunction. Apart from 
right heart abnormalities, there was no significant change in the proportions of left heart cardiac 
abnormalities at follow up (Table 1). We observed an overall increase in mean z-scores for LV, 
LA, RV, interventricular septum and LV posterior wall diameters and TAPSE for all 
participants at follow up (p<0.001) (Table 1).  Table 2 shows mean baseline and 18 months z-
scores and adjusted mean (SD) change in z-scores for cardiac parameters and estimated risk 
for cardiac abnormalities. The risk of developing RV dilatation was highest 12/163 (7%) with 
mean (SD) z-score for RV diameter at baseline of +1.10 (0.7) and increased to +2.51 (0.5). Of 
those with RV dilatation at follow up, n=4 had mild tricuspid regurgitation and n=7 had mild 
pulmonary regurgitation, two of whom had both tricuspid and pulmonary regurgitation. There 
was a negative correlation between change in z-score and baseline z-scores, e.g. participants 
with high z-scores at baseline had a smaller change in z-score at follow up. Mean changes in 
z-scores adjusted for baseline z-score of the same parameter were 0.64 SD (95% CI: 0.52, 0.77) 
for RV diameter; 0.36 SD (95% CI: 0.25, 0.47) for LV diameter; 0.63 SD (95% CI: 0.52, 0.74) 
for IVS diameter; 0.74 SD (95% CI: 0.63, 0.85) for LVPW diameter; 0.42 SD (95% CI: 0.33, 
0.51) for LA diameter and -0.06 SD (95% CI: -0.24, 0.13) for TAPSE. Overall, 10 participants 
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developed left heart abnormalities and 16 developed right heart abnormalities at 18 months, 
giving an estimated incidence of 3.52/100 pys and 5.64/100 pys, respectively.  
Of the 23 (13%) participants who had RV dilatation at follow up, 10 (43%) had concurrent left 
heart abnormalities and 11 (48%) also had RV dilation at baseline. Of the 6 participants with 
RV systolic dysfunction at 18 months, two had systolic dysfunction at baseline. None of the 
participants met criteria for pulmonary hypertension by echocardiography. LVH was present 
in 15 (9%) participants at follow up, of whom 13/15 (87%) also had LVH at baseline and 3 
(20%) and 5 (33%) had LA dilatation and LV diastolic dysfunction, respectively, at baseline. 
LV dilatation persisted from baseline in 7 (4%) participants, 2 of whom had concurrent LA 
dilatation at baseline and follow up. Regression of abnormalities was observed in 11(6%) 
participants; two had LV systolic dysfunction, five had LVH (one with concurrent LV systolic 
dysfunction), five had isolated LV diastolic dysfunction (one with concurrent LVH) and one 
had RV dilatation at baseline. Cardiorespiratory symptoms were reported by 48/175 (27%) at 
baseline and of these 85% were asymptomatic at 18 months.  
On multivariate logistic regression, stunting was associated with development of any new 
cardiac abnormality (adjusted OR 2.59 (95% CI, 1.03- 6.49; p=0.043). No HIV-related factors, 
including CD4 count, viral load, duration on ART, age at ART initiation and type of ART, 
were associated with incidence of any cardiac abnormalities. Supplementary Table 1 shows the 
type of ART and proportion of participants receiving the different drugs. There was no 
association between incidence of right heart abnormalities and abnormal spirometry. Menarche 
or the different indices of pubertal growth were not associated with change in mean z-scores 
for cardiac dimensions (data not shown). On linear regression, no association was observed 
between baseline factors and mean change in z-scores for cardiac dimensions (supplementary 
Table 2).  
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Discussion 
To our knowledge, this is the first cohort study from SSA reporting the incidence and 
progression of cardiac abnormalities in children taking ART. Despite ART, participants 
continue to develop cardiac abnormalities, with the highest risk being development of RV 
dilatation, which was not associated with abnormal lung function. Most of the children with 
RV dilatation had isolated dilatation without associated RV systolic dysfunction. Currie et al, 
reported that heart muscle disease among people with HIV manifests as global or borderline 
LV dysfunction and isolated RV dilatation, [18] and we hypothesise that the isolated RV 
dilatation observed in the present study may be part of the spectrum of HIV-related 
cardiomyopathy and that it is manifest before LV involvement becomes apparent. Isolated RV 
enlargement has been previously reported in adults with HIV who had preserved LV function 
[19]. Notably, none of the participants with RV dilatation met the criteria for pulmonary 
hypertension using Doppler echocardiography, although we acknowledge that right heart 
cardiac catheterisation is the gold standard in diagnosing pulmonary hypertension. Despite the 
limitations of Doppler echocardiography in assessment of right heart pressures in children, 
there was no association between right heart abnormalities and abnormal lung function, further 
suggesting that the abnormalities are more likely due to primary heart muscle disease. 
Most cardiac abnormalities present at baseline persisted at follow up, and we observed an 
overall increase in mean z-scores for cardiac dimensions over this short period of follow up. 
However, the majority had no symptoms, suggesting that there may be a prolonged period of 
subclinical cardiac abnormalities before overt disease develops. The results of our study 
suggest the potential for progression of cardiac abnormalities and highlight the importance of 
routine screening for cardiac disease in children with HIV, even in the absence of symptoms. 
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A minority of participants had transient cardiac abnormalities. LV systolic dysfunction and 
LVH may have been a consequence of an acute infectious myocarditis [20]. Transient 
ventricular wall thickening has previously been observed in participants with acute myocarditis 
[21]. The participant with RV dilatation at baseline which resolved by follow up had a 
respiratory tract infection near time of the initial echocardiogram, which then resolved. Lung 
infection may result in transient pulmonary hypertension and RV enlargement, which resolve 
with effective treatment of the infection [22]. Reversible cardiac abnormalities have also been 
reported among HIV infected adults in the USA, more than two-thirds (71%) of whom had 
AIDS [23].  
 
The aetiology of myocardial disease in HIV infection is complex. Several pathogenic 
mechanisms have been hypothesised, including chronic systemic immune activation of cardiac 
myocytes that occurs in HIV infection and is not completely reversed by ART [24]. Infection 
of the heart by opportunistic pathogens, including cytomegalovirus, Epstein Barr virus, 
coxsackievirus and adenovirus, may also result in cardiac damage [25]. Cardiotoxicity from 
ART has also been suggested, particularly nucleoside reverse transcriptase inhibitors (NRTIs), 
the backbone of ART including abacavir, and zidovudine [26, 27]. This may be related to 
mitochondrial dysfunction, which has been observed following use of stavudine, didanosine 
and zidovudine, while abacavir reportedly increases risk of myocardial infarction in adults [28]. 
Abacavir and zidovudine were being taken by 4% and 52% of the participants, respectively, 
but no association between antiretroviral drugs and cardiac abnormalities was identified in this 
study. This further supports the possibility of the abnormalities being due to primary heart 
muscle disease. 
Stunted children had a higher likelihood of developing cardiac abnormalities. Miller et al. also 
reported that stunting was associated with LV diastolic dysfunction in their retrospective study 
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of HIV infected adolescents, 71% of whom were on ART [29]. Stunting is a marker of chronic 
inflammatory conditions in childhood and underlying systemic inflammation may also play a 
role in pathogenesis of cardiac disease [30, 31]. Notably, the proportion of participants who 
were virally non-suppressed had increased over the follow up period. Poor adherence and high 
rates of viral non-suppression among adolescents have been reported previously [32]. This 
would mean ongoing viral replication which is in turn associated with dysregulated systemic 
immune activation.  In adults with HIV, systemic immune activation is a risk factor for 
development of cardiac disease [30]. HIV persists in reservoir cells even after effective 
treatment with ART and may continue to release cytotoxic cytokines which subsequently 
contribute to progressive and late tissue damage (cardiac myocytes) [33]. The median age of 
ART initiation in this cohort was 6 (IQR, 3-8) years and immunosuppression and opportunistic 
infections prior to ART initiation may cause cardiac damage. Poor adherence to ART may also 
explain the higher incidence of cardiac disease in our cohort compared to previous studies in 
high-income settings [9]. 
 
Strengths and limitations 
This study is the first to report the incidence and progression of cardiac disease in a paediatric 
HIV population from SSA, where the vast majority of children with HIV live. The main 
strengths include the prospective, systematic evaluation for cardiac abnormalities and use of 
local reference ranges to define the abnormalities, rather than reference ranges derived from 
North American or European populations, which have been shown not to be appropriate for 
SSA [34, 35]. Furthermore, participants were consecutively enrolled and not selectively 
enrolled on the basis of symptoms. Limitations of the study include lack of viral load measures 
on all participants and as a result, we may have been underpowered to detect any associations 
between incident cardiac disease and viral load. Study of biomarkers was not within the scope 
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of this study but, we do have stored blood samples and investigation of systemic markers of 
inflammation is ongoing. The use of advanced echocardiographic techniques such as three-
dimensional echocardiography may have provided more imaging by allowing direct calculation 
of chamber volumes as well as global or regional function through elimination of geometric 
assumptions used in M-mode and minimised the errors arising from foreshortened apical views. 
Notably, we only used optimum images to acquire the various measurements from in this study. 
Speckle tracking imaging would have been more sensitive to detecting subclinical ventricular 
function, which may not be identified by measurement of the LV ejection fraction. Tissue 
doppler imaging may have assessed LV diastolic dysfunction better because it is less dependent 
on loading conditions compared to transmitral inflow velocities. However, we also included 
pulmonary venous flow velocities which provided additive value to the evaluation of LV 
diastolic function.  Importantly, this study was performed in a resource-limited setting and use 
of more contemporary imaging measures was not available. In most healthcare settings in this 
region, there is not widespread availability of advanced echocardiographic techniques and so 
our findings will be more readily applicable to a low-resource setting, which is where the 
majority of these patients are seen.  
 
Conclusion 
There is a high incidence of cardiac abnormalities in children with HIV and taking ART in 
SSA and the lack of association with lung and HIV factors suggests that these abnormalities 
are primary HIV-related heart muscle disease. There is some evidence of disease progression 
over a short follow up period. Longer follow up is needed to understand the clinical 
implications of these abnormalities, and the pathogenesis of these abnormalities needs further 
study.  
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Figure 1. Flow chart for participant recruitment and follow up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of children with echocardiograms at baseline 
(n =197) 
18
 M
o
n
th
s 
fo
llo
w
 u
p
 
B
as
el
in
e 
Abnormal echocardiograms 
(n =60) 
Normal echocardiograms 
(n = 137) 
Number of children lost to follow up 
(50% had cardiac abnormalities) 
(n =22) 
Total number of children with echocardiograms at follow up and 
analysed 
(N=175) 
Number of children who died (all had 
cardiac abnormalities) 
(N=4) 
 
18 
 
Table 1. Clinical characteristics of participants 
Variable N=175 P-value 
 Baseline 
Mean (SD) 
18 Months 
Mean (SD) 
 
Female, N (%) 84 (48)  
Age, y (median, IQR) 11 (9 – 13) 12 (10 – 14) <0.001 
CD4, cell/μl (median, IQR) 726 (473 - 935) 734 (462 - 989) * 0.455 
Viral load, copies/ml, (median, IQR) 19 (19 - 208) 456 (165 - 4080) ** <0.001 
Duration on ART, y (median, IQR) 4.8 (2.8 - 6.4) 6.5 (4.3 - 8.1) <0.001 
Systolic Blood Pressure, mmHg 110 (11)  109 (10) 0.247 
Diastolic Blood Pressure, mmHg 73 (9)  72 (9) 0.392 
Respiratory rate, breaths per min 21.8 (4.5) 21.9 (2.3) 0.697 
Signs and Symptoms n (%) 
Chest pains on exertion  20 (11) 5 (3) <0.001 
Tachycardia  10 (6) 6 (3) 0.317 
Tachypnoea 24 (14) 10 (6) 0.013 
Hypoxia at rest 1 (1) 0 - 
Abnormal spirometry*** 37 (24) 23 (15) 0.144 
Wasting  38 (22) 35 (20) 0.106 
Stunting  40 (23) 39 (22) 0.117 
Cardiac Measures  
RV diameter z-score 0.40 (1.3) 0.91 (1.1) <0.001 
LV diameter z-score 0.49 (1.1) 0.72 (1.1) <0.001 
IVS diameter z-score 0.06 (1.0) 0.65 (0.8) <0.001 
LVPW diameter z-score 0.29 (1.2) 0.88 (0.9) <0.001 
LA diameter z-score 0.36 (1.1) 0.66 (1.0) <0.001 
TAPSE -0.63 (0.9) -0.26 (1.0) <0.001 
Ejection fraction (%) 61.7 (6.2) 64.5 (6.6) <0.001 
E wave (m/s) 0.91 (0.1) 0.93 (0.2) 0.142 
A wave (m/s) 0.53 (0.1) 0.55 (0.1) 0.105 
E/A ratio 1.76 (0.4) 1.74 (0.4) 0.656 
Deceleration Time (ms) 174 (27.7) 169 (15.6) 0.044 
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PV S wave (m/s) 0.49 (0.1) 0.51 (0.1) 0.069 
PV D wave (m/s) 0.55 (0.5) 0.51 (0.1) 0.388 
PV A wave (m/s) 0.19 (0.2) 0.22 (0.5) 0.352 
PV S/D ratio 0.98 (0.3) 1.02 (0.2) 0.062 
Cardiac abnormalities n (%) 
LV dilatation  7 (4) 8 (5) 0.317 
LVH 18 (10) 15 (9) 0.257 
LA dilatation  14 (8) 15 (9) 0.317 
LV systolic dysfunction 2 (1) 1 (1) 0.563 
LV diastolic dysfunction 40 (23) 40 (23) 1.000 
RV dilatation 12 (7) 23 (13) 0.002 
RV systolic dysfunction 2 (1) 6 (3) 0.046 
Tricuspid regurgitation 31 (18) 34 (20) 0.564 
Mitral regurgitation 5 (3) 3 (2) 0.317 
Pulmonic regurgitation 37 (21) 28 (16) <0.001 
Aortic regurgitation - - - 
 
*, n=159; **, n=91; ***, n=150 
LV, left ventricle; IVS, interventricular septum, LA, left atrium; RV, right ventricle; E/A ratio, mitral 
valve peak early to late left ventricular filling velocity; PV, pulmonary venous; S, systolic; D, 
diastolic; TAPSE, tricuspid annular plane systolic excursion 
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Table 2. Z-scores at baseline and follow up for participants 
Cardiac variable Baseline Follow up N (%) Z-score baseline 
mean (SD) 
Z-score 18 months 
mean (SD) 
Adjusted change in z-
score after 18 months, SD 
(95% CI) 
P-value Risk 
RV diameter diastole Normal Normal 151 (86) 0.15 (1.1) 0.64 (0.9) 0.55 (0.43- 0.67)  <0.001  
 Normal RV dilatation 12 (7) 1.10 (0.7) 2.51 (0.5) 2.47 (1.90- 3.03) <0.001 12/163 (7%) 
 RV dilatation Normal 1 (1) 2.23 (0.0) 1.81 (0.0) -0.79 a    
 RV dilatation RV dilatation 11 (6) 2.91 (0.7) 2.85 (0.8) 0.59 (-1.21- 2.39) 0.478  
LV diameter diastole Normal Normal 167 (95) 0.37 (1.0) 0.62 (1.0) 0.35 (0.24- 0.47) <0.001  
 Normal LV dilatation 1 (1) 1.04 2.10 1.06 a  1/168 (1%) 
 LV dilatation LV dilatation 7 (4) 3.27 (0.3) 2.94 (0.4) -0.46 (-2.20- 1.27) 0.523  
IVS diameter diastole Normal Normal 172 (98) 0.02 (0.9) 0.62 (0.8) 0.61 (0.51- 0.71) <0.001  
 Normal IVS hypertrophy 2 (1) 1.82 (0.2) 3.13 (1.1) 1.31 (1.3)  2/174 (1%) 
 IVS hypertrophy Normal 1 (1) 2.50 1.63 -0.87 a   
LVPW diameter diastole Normal Normal 158 (90) 0.05 (1.0) 0.72 (0.8) 0.70 (0.59- 0.81) <0.001  
 LVPW hypertrophy Normal 4 (2) 2.43 (0.2) 1.63 (0.2) -0.80 (0.4) a   
 LVPW hypertrophy LVPW hypertrophy 13 (7) 2.61 (0.5) 2.61 (0.4) 1.00 (0.11- 1.89) 0.032  
LA diameter diastole Normal Normal 160 (91) 0.17 (1.0) 0.52 (0.9) 0.41 (0.31- 0.50) <0.001  
 Normal LA dilatation 1 (1) 1.99 2.07 0.08 a  1/161 (1%) 
 LA dilatation LA dilatation 14 (8) 2.44 (0.3) 2.44 (0.2) 2.74 (1.77-3.70) <0.001  
TAPSE Normal Normal 154 (88) -0.59 (0.9) -0.16 (1.0) -0.04 (0.22-0.14) 0.673  
 Normal RV systolic dysfunction 4 (2) -1.36 (0.6) -2.32 (0.3) -0.96 (0.8) a  4/158 (3%) 
 RV systolic dysfunction RV systolic dysfunction 2 (1) -2.23 (0.1) -2.20 (0.1) -0.02 (0.1) a   
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a , unadjusted change (if n=1), or adjusted mean and (SD if n>1) has been reported; RV, right ventricle; LV, left ventricle; IVS, interventricular septum, 
LVPW, left ventricular posterior wall; LA, left atrium, TAPSE, tricuspid annular plane systolic excursion
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Supplementary figure 1: Flow diagram of viral suppression of participants over time 
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Supplementary Table 1: Antiretroviral drugs received by participants 
 
 
Antiretroviral drug 
 
(N=175)      n (%) 
Zidovudine 91 (52) 
Stavudine 1 (1) 
Tenofovir 75 (43) 
lamivudine 173 (99) 
Didanosine 2 (1) 
Abacavir 7 (4) 
Atazanavir 7 (4) 
Lopinavir/ritonavir (Aluvia) 8 (5) 
Atazanavir/ritonavir 28 (16) 
Nevirapine 61 (35) 
Efavirenz 39 (22) 
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Supplementary Table 2: Association between change in z-scores and baseline risk factors 
 
Variables  RV diameter LV diameter IVS diameter LVPW diameter LA diameter TAPSE diameter 
 Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value Coefficient P-value 
Age             
6 – 9 years 1 0.78 1 0.69 1 0.80 1 0.80 1 0.26 1 0.46 
10 -12 years -0.080  -0.071  -0.004  -0.089  -0.167  0.006  
13 – 16 years -0.099  -0.117  -0.087  0.198  -0.081  -0.027  
Viral load             
≤ 400 copies/ml 1            
> 400 copies/ml -0.119 0.41 0.034 0.79 0.170 0.20 0.080 0.55 0.002 0.99 -0.120 0.41 
CD4 count             
≥ 350 cell/μl 1            
<350 cell/μl 0.202 0.32 0.154 0.39 0.110 0.55 0.060 0.75 0.041 0.78 -0.275 0.30 
Duration on ART             
0 – 3 years 1 0.96 1 0.34 1 0.68 1 0.43 1 0.40 1 0.60 
4 – 7 years 0.009  0.171  -0.093  0.155  -0.067  0.174  
8 – 12 years 0.054  0.126  0.019  0.098  0.201  0.126  
Age at ART 
initiation 
            
0 -5 years 1 0.07 1 0.65 1 0.80 1 0.92 1 0.75 1 0.06 
6 – 10 years 0.320  -0.035  0.040  0.009  -0.056  0.196  
11 – 15 years 0.169  -0.184  0.133  0.265  0.050  -0.531  
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Height-for-age z-
scores 
-0.085 0.13 -0.035 0.42 0.015 0.73 -0.092 0.06 -0.023 0.57 -0.048 0.56 
             
Weight -for-age z-
scores 
-0.001 1.00 -0.008 0.86 0.044 0.33 -0.062 0.22 -0.049 0.23 -0.032 0.67 
 
RV, right ventricle; LV, left ventricle; IVS, interventricular septum, LVPW, left ventricular posterior wall; LA, left atrium, TAPSE, tricuspid annular plane 
systolic excursion 
